Form 4: ALX Oncology CFO Granted Stock Options

ALX Oncology Holdings Inc.'s Chief Financial Officer, Harish Shantharam, was granted 198,750 employee stock options with an exercise price of $1.7.

Summary

• Harish Shantharam, Chief Financial Officer of ALX Oncology Holdings Inc. (ALXO), was granted 198,750 employee stock options.
• The options have an exercise price of $1.7 per share.
• The grant date for these options was October 14, 2025.
• The options are scheduled to expire on October 14, 2035.
• Vesting occurs in two tranches: one-third of the shares vest on April 30, 2026, and the remaining two-thirds vest on October 31, 2026.

Sentiment

Score: 6

Explanation: The grant of stock options to a key executive is a standard practice for aligning management incentives with shareholder interests and promoting long-term retention. It is a routine compensation event rather than a significant operational or financial announcement.

Positives

• The grant of stock options to the Chief Financial Officer aligns management's interests with shareholder value creation.
• The options have a 10-year expiration period, providing a long-term incentive for performance.

Negatives

• Potential future dilution for existing shareholders if and when these options are exercised.

Risks

• The value of the options is dependent on the future market price of ALX Oncology Holdings Inc. common stock exceeding the $1.7 exercise price.
• The options are subject to vesting conditions, meaning the CFO must remain employed by the company until the vesting dates to realize the full benefit.

Future Outlook

The vesting schedule indicates that the Chief Financial Officer will gain beneficial ownership of the shares underlying the options in two tranches during 2026, contingent on continued employment. This structure is designed to incentivize long-term performance and retention.

Industry Context

The grant of employee stock options is a common practice in the biotechnology and pharmaceutical industries, particularly for executive compensation. It serves to align the interests of key management personnel with those of shareholders by providing an equity stake and incentivizing long-term growth and performance.

Comparison to Industry Standards

• The grant of stock options to a Chief Financial Officer is a standard component of executive compensation packages across publicly traded companies, especially within the biotech sector.
• While specific terms like the number of options and exercise price vary based on company size, performance, and individual roles, the structure of a multi-year vesting schedule and a 10-year expiration date is typical for long-term incentive plans.
• No specific comparable companies or projects are mentioned in the filing to allow for a direct quantitative comparison, but the qualitative nature of the grant aligns with general industry practices.

Stakeholder Impact

• Shareholders: Potential for minor future dilution if options are exercised, but also increased alignment of management's interests with shareholder value.
• Employees: Standard executive compensation practices can set a precedent or benchmark for other employee incentive programs.

Next Steps

• Vesting of one-third of the options on April 30, 2026.
• Vesting of the remaining two-thirds of the options on October 31, 2026.
• Potential exercise of options by the Chief Financial Officer at any time after vesting and before the expiration date.

Key Dates

Recommendation

This Form 4 reports a routine grant of employee stock options to a Chief Financial Officer as part of their compensation package. Such a transaction, while aligning management incentives, does not provide new fundamental information about the company's operations, financial performance, or strategic direction that would warrant a change in investment recommendation. It is an expected part of executive compensation.

Keywords

ALX Oncology, ALXO, stock options, Form 4, insider transaction, executive compensation, Harish Shantharam, equity grant